JNJ-61186372 has been uniquely designed to target both EGFR and c-Met on NSCLC cells through multiple mechanism of action including signaling inhibition of both pathways and activation of Fc effector cells through the EGFR arm.18 This evidence concerns the gene EGFR and non-small cell lung carcinoma.